These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 22066310)

  • 1. Omalizumab 75 mg. Whatever the dosage, the drug should be avoided in severe persistent asthma.
    Prescrire Int; 2011 Nov; 20(121):262. PubMed ID: 22066310
    [No Abstract]   [Full Text] [Related]  

  • 2. Granulomatous foreign-body reaction with facial dermal fillers after omalizumab treatment for severe persistent allergic asthma: a case report.
    Dammak A; Taillé C; Marinho E; Crestani B; Crickx B; Descamps V
    Br J Dermatol; 2012 Jun; 166(6):1375-6. PubMed ID: 22233356
    [No Abstract]   [Full Text] [Related]  

  • 3. Omalizumab in the treatment of asthma.
    Tan R; Corren J
    Expert Rev Respir Med; 2011 Dec; 5(6):747-56. PubMed ID: 22082161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drugs to avoid during pregnancy: omalizumab and montelukast, too many uncertainties.
    Prescrire Int; 2014 Feb; 23(146):51. PubMed ID: 24669391
    [No Abstract]   [Full Text] [Related]  

  • 5. Allergic bronchopulmonary aspergillosis and omalizumab.
    Tillie-Leblond I; Germaud P; Leroyer C; Tétu L; Girard F; Devouassoux G; Grignet JP; Prudhomme A; Dusser D; Wallaert B
    Allergy; 2011 Sep; 66(9):1254-6. PubMed ID: 21517902
    [No Abstract]   [Full Text] [Related]  

  • 6. [Omalizumab treatment in patients with asthma: summary of Meir Medical Center experience with 47 patients].
    Shitrit D; Talker O; Metabichek A; Yaakovi I
    Harefuah; 2012 Apr; 151(4):216-9, 254, 253. PubMed ID: 22616149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Omalizumab: a novel steroid sparing agent in eosinophilic granulomatosis with polyangiitis?
    Latorre M; Baldini C; Seccia V; Notarstefano C; Della Rossa A; Tani C; Talarico R; Mosca M; Paggiaro PL
    Clin Exp Rheumatol; 2013; 31(1 Suppl 75):S91-2. PubMed ID: 23075542
    [No Abstract]   [Full Text] [Related]  

  • 8. Omalizumab under 12 years old: real-life practice.
    Pite H; Gaspar Â; Paiva M; Leiria-Pinto P
    Allergol Immunopathol (Madr); 2013; 41(2):133-6. PubMed ID: 22560014
    [No Abstract]   [Full Text] [Related]  

  • 9. Summaries for patients. Omalizumab therapy for patients with severe asthma.
    Ann Intern Med; 2011 May; 154(9):I28. PubMed ID: 21536934
    [No Abstract]   [Full Text] [Related]  

  • 10. Churg-Strauss syndrome in a patient treated with omalizumab.
    Cisneros C; Segrelles G; Herráez L; Gonzalez A; Girón R
    J Investig Allergol Clin Immunol; 2013; 23(7):515-6. PubMed ID: 24654320
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical benefits of 7 years of treatment with omalizumab in severe uncontrolled asthmatics.
    Pace E; Ferraro M; Bruno A; Chiappara G; Bousquet J; Gjomarkaj M
    J Asthma; 2011 May; 48(4):387-92. PubMed ID: 21391878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Thrombocytopenia due to omalizumab].
    Lopez-Rodriguez JA; Santos Franco L
    An Pediatr (Barc); 2014 Jun; 80(6):413-4. PubMed ID: 24246236
    [No Abstract]   [Full Text] [Related]  

  • 13. Omalizumab: NICE to USE you, to LOSE you NICE.
    Bush A; Pavord ID
    Thorax; 2013 Jan; 68(1):7-8. PubMed ID: 23229814
    [No Abstract]   [Full Text] [Related]  

  • 14. Persistent elevation of peripheral blood myeloid cell counts associated with omalizumab therapy.
    Banh HL; Trevoy J; Pabst H; Beach J; Vethanayagam D
    Am J Health Syst Pharm; 2012 Feb; 69(4):302-6. PubMed ID: 22302255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR.
    Vignola AM; Humbert M; Bousquet J; Boulet LP; Hedgecock S; Blogg M; Fox H; Surrey K
    Allergy; 2004 Jul; 59(7):709-17. PubMed ID: 15180757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Omalizumab: new drug. Asthma: too many unknowns for an anti-IgE.
    Prescrire Int; 2007 Oct; 16(91):179-82. PubMed ID: 17926440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Omalizumab and the risk of malignancy: results from a pooled analysis.
    Busse W; Buhl R; Fernandez Vidaurre C; Blogg M; Zhu J; Eisner MD; Canvin J
    J Allergy Clin Immunol; 2012 Apr; 129(4):983-9.e6. PubMed ID: 22365654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma.
    Ayres JG; Higgins B; Chilvers ER; Ayre G; Blogg M; Fox H
    Allergy; 2004 Jul; 59(7):701-8. PubMed ID: 15180756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pneumology. Anti-IgE antibodies in the treatment of asthma].
    Leuenberger P; Sauty A; Rochat T
    Rev Med Suisse; 2007 Jan; 3(93):56-9. PubMed ID: 17354662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Omalizumab in the treatment of severe asthma: efficacy and current problems.
    Pelaia G; Renda T; Romeo P; Busceti MT; Maselli R
    Ther Adv Respir Dis; 2008 Dec; 2(6):409-21. PubMed ID: 19124386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.